Sunflower Bank N.A. Purchases 37 Shares of Stryker Co. (NYSE:SYK)

Sunflower Bank N.A. increased its position in shares of Stryker Co. (NYSE:SYK) by 5.9% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 665 shares of the medical technology company’s stock after buying an additional 37 shares during the period. Sunflower Bank N.A.’s holdings in Stryker were worth $239,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Main Street Financial Solutions LLC boosted its position in shares of Stryker by 19.8% during the 2nd quarter. Main Street Financial Solutions LLC now owns 709 shares of the medical technology company’s stock valued at $241,000 after purchasing an additional 117 shares in the last quarter. Federated Hermes Inc. grew its position in shares of Stryker by 16.2% during the 2nd quarter. Federated Hermes Inc. now owns 113,916 shares of the medical technology company’s stock worth $38,760,000 after buying an additional 15,882 shares during the period. HBK Sorce Advisory LLC bought a new position in Stryker during the second quarter worth $241,000. Parallel Advisors LLC grew its holdings in Stryker by 2.0% in the second quarter. Parallel Advisors LLC now owns 15,311 shares of the medical technology company’s stock worth $5,209,000 after purchasing an additional 300 shares during the period. Finally, Oppenheimer Asset Management Inc. increased its stake in Stryker by 11.9% in the second quarter. Oppenheimer Asset Management Inc. now owns 35,282 shares of the medical technology company’s stock valued at $12,005,000 after purchasing an additional 3,765 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. JPMorgan Chase & Co. raised their target price on Stryker from $375.00 to $420.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. Canaccord Genuity Group boosted their price objective on Stryker from $360.00 to $400.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Piper Sandler reiterated an “overweight” rating and issued a $420.00 target price (up from $380.00) on shares of Stryker in a report on Wednesday, October 30th. Barclays boosted their price target on shares of Stryker from $402.00 to $418.00 and gave the company an “overweight” rating in a research note on Thursday, October 31st. Finally, StockNews.com raised shares of Stryker from a “hold” rating to a “buy” rating in a research note on Thursday. Four analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $405.80.

Stryker Stock Performance

Shares of SYK traded down $4.70 during trading hours on Monday, hitting $360.96. The company’s stock had a trading volume of 1,400,602 shares, compared to its average volume of 1,302,026. The company has a market cap of $137.60 billion, a price-to-earnings ratio of 38.69, a PEG ratio of 2.82 and a beta of 0.95. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The business has a 50 day simple moving average of $375.40 and a two-hundred day simple moving average of $357.95. Stryker Co. has a 52-week low of $307.23 and a 52-week high of $398.20.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business had revenue of $5.49 billion for the quarter, compared to analysts’ expectations of $5.37 billion. During the same quarter in the prior year, the firm posted $2.46 EPS. The firm’s quarterly revenue was up 11.9% on a year-over-year basis. On average, equities analysts expect that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Stryker Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be paid a dividend of $0.84 per share. This is a positive change from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date is Tuesday, December 31st. This represents a $3.36 annualized dividend and a yield of 0.93%. Stryker’s dividend payout ratio (DPR) is currently 36.01%.

Insider Buying and Selling

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at $36,879,954.90. The trade was a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.90% of the stock is owned by company insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.